Sex and sex by treatment group interactions were added to examine the effect of gender on the primary and secondary efficacy outcomes in a randomized clinical trial that tested the efficacy of vilazodone, a selective serotonin receptor inhibitor and partial 5-HT1A agonist, for treatment of cannabis dependence [58]. This evidence concerns the gene HTR1A and cannabis dependence.